A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 6, 2021

Primary Completion Date

January 19, 2022

Study Completion Date

April 21, 2022

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Spesolimab - solution for infusion

Solution for infusion

DRUG

Placebo matching spesolimab - solution for infusion

Solution for infusion

DRUG

Spesolimab- solution for injection

Solution for injection

DRUG

Placebo matching to spesolimab- solution for injection

Solution for injection

Trial Locations (25)

1070

ULB Hopital Erasme, Brussels

2010

Holdsworth House Medical Practice, Sydney

3050

Royal Melbourne Hospital, Parkville

8005

Nordlandssykehuset HF, Bodø, Bodø

15213

University of Pittsburgh Medical Center, Pittsburgh

31059

HOP Larrey, Toulouse

42624

Non-Public Health Care Facility LABDERM, Ossy

44791

Katholisches Klinikum Bochum gGmbH, Bochum

46250

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

51430

CLI Reims Bezannes, Bezannes

55905

Mayo Clinic, Rochester, Rochester

56126

Azienda Ospedaliera Universitaria Pisana, Pisa

60123

Ospedali Riuniti di Ancona, Ancona

60596

Universitätsklinikum Frankfurt, Frankfurt am Main

69003

HOP Edouard Herriot, Lyon

73118

Unity Clinical Research, Oklahoma City

90045

Dermatology Research Associates, Los Angeles

L3Y 5G8

Dr. S. K. Siddha Medicine Professional Corporation, Newmarket

708 52

University Hospital Ostrava, Ostrava

06847

Städtisches Klinikum Dessau, Dessau

3015 GD

Erasmus Medisch Centrum, Rotterdam

N-5021

Haukeland Universitetssykehus, Bergen

N-0372

Oslo Universitetssykehus HF, Rikshospitalet, Oslo

50-566

Cityclinic Medical and Psychological Clinic Matusiak Partnership, Wroclaw

08026

Hospital Santa Creu i Sant Pau, Barcelona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY